A Phase 3 interventional study of Naltrexone SR 32 mg/bupropion SR 360 mg/day and Placebo in Obesity and Overweight, sponsored by Orexigen Therapeutics, Inc. Completed at 36 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-11-21.
Sponsored by Orexigen Therapeutics, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing naltrexone in Obesity — 4 open to participants now, 4 under way, none of them phase 3. Naltrexone · Obesity.
Among the 23 studies testing naltrexone in Obesity, this one is the 3rd largest by enrollment, is one of 5 that started in 2007, is one of 6 in phase 3, and was the 6th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →4 of the 23 studies testing naltrexone in Obesity are open now, in 2 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–65
Laval University · Sites in Canada
Ages 18–65
Medical University of South Carolina · Sites in United States
Ages 18–65
Medical University of South Carolina · Sites in United States
Ages 18–65
By country, each count listing its studies:
Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 7 · Phase 4 6
First in 2005; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,496 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 67 across the 23 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 10 most frequent:
Orexigen Therapeutics, Inc is the lead sponsor of 18 studies on the registry; none are open to participants now.
14 studies in Obesity by Orexigen Therapeutics, Inc: none open now, none under way, none of them phase 3. Of 14 finished, 8 (57%) have results posted.
Among the 14 studies in Obesity by Orexigen Therapeutics, Inc, this one is the 3rd largest by enrollment, is one of 5 that started in 2007, is one of 6 in phase 3, and was the 7th registered.
Orexigen Therapeutics, Inc’s Obesity studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing naltrexone in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Orexigen Therapeutics, Inc’s 14 in Obesity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity.
Two Phase II clinical trials demonstrated that a combination of bupropion SR and naltrexone is associated with greater weight loss than naltrexone alone, bupropion SR alone or placebo in subjects with uncomplicated obesity. The current study investigated the safety and efficacy of the combination of naltrexone SR and bupropion SR compared to placebo in obese subjects with uncomplicated obesity and in those with overweight/obesity and hypertension and/or dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Naltrexone SR 32 mg/bupropion SR 360 mg/day with ancillary therapy
Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day · Behavioral: Ancillary therapy
Placebo with ancillary therapy
Drug: Placebo · Behavioral: Ancillary therapy
Drug page: Naltrexone
Also known as: NB32
Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28
Time frame: Baseline, 28 weeks
Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28
Time frame: Baseline, 28 weeks
Body Weight- Mean Percent Change From Baseline to Week 56
Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis. Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48).
Time frame: Baseline, 56 weeks
Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56
Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis. Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48).
Time frame: Baseline, 56 weeks
Body Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 28
Time frame: Baseline, 28 weeks
Change in Waist Circumference
Time frame: Baseline, 28 weeks
Change in Fasting HDL Cholesterol Levels
Time frame: Baseline, 28 weeks
Change in Fasting Triglycerides Levels, Using Log-transformed Data
Time frame: Baseline, 28 weeks
Change in IWQOL-Lite Total Scores
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment
Time frame: Baseline, 28 weeks
Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data
Time frame: Baseline, 28 weeks
Change in Fasting Insulin Levels, Using Log-transformed Data
Time frame: Baseline, 28 weeks
Change in Fasting Blood Glucose Levels
Time frame: Baseline, 28 weeks
Change in HOMA-IR Levels, Using Log-transformed Data
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance
Time frame: Baseline, 28 weeks
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult
Time frame: Baseline, 28 weeks
Change in Fasting LDL Cholesterol Levels
Time frame: Baseline, 28 weeks
Change in Systolic Blood Pressure
Time frame: Baseline, 28 weeks
Change in Diastolic Blood Pressure
Time frame: Baseline, 28 weeks
Change in IDS-SR Total Score
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.
Time frame: Baseline, 28 weeks
Change in Food Craving Inventory Sweets Subscale Score
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).
Time frame: Baseline, 28 weeks
Change in Food Craving Inventory Carbohydrates Subscale Score
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).
Time frame: Baseline, 28 weeks
| Milestone | NB32 | Placebo |
|---|---|---|
| Started | 1001 | 495 |
| Completed | 538 | 267 |
| Not completed | 463 | 228 |
| Withdrew: Adverse event | 241 | 68 |
| Withdrew: Lost to follow-up | 77 | 48 |
| Withdrew: Withdrawal by subject | 75 | 56 |
| Withdrew: Lack of efficacy | 19 | 33 |
| Withdrew: Protocol violation | 20 | 8 |
| Withdrew: Pregnancy | 6 | 0 |
| Withdrew: Drug noncompliance,moved,other | 25 | 15 |
| percentage of body weight | NB32 | Placebo |
|---|---|---|
| Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28 | -6.45 ± 0.20 | -1.89 ± 0.26 |
Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis. Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48).
| percentage of body weight | NB32 | Placebo |
|---|---|---|
| Body Weight- Mean Percent Change From Baseline to Week 56 | -6.40 ± 0.25 | -1.23 ± 0.33 |
| percentage of participants | NB32 | Placebo |
|---|---|---|
| Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28 | 55.64 (52.25 to 59.03) | 17.54 (14.05 to 21.03) |
Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis. Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48).
| percentage of participants | NB32 | Placebo |
|---|---|---|
| Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56 | 50.48 (46.90 to 54.07) | 17.11 (13.46 to 20.75) |
| percentage of participants | NB32 | Placebo |
|---|---|---|
| Body Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 28 | 27.27 (24.23 to 30.31) | 7.02 (4.67 to 9.36) |
| cm | NB32 | Placebo |
|---|---|---|
| Change in Waist Circumference | -6.16 ± 0.28 | -2.74 ± 0.38 |
| mg/dL | NB32 | Placebo |
|---|---|---|
| Change in Fasting HDL Cholesterol Levels | 1.19 ± 0.30 | -1.40 ± 0.42 |
| percent change | NB32 | Placebo |
|---|---|---|
| Change in Fasting Triglycerides Levels, Using Log-transformed Data | -7.32 (-9.80 to -4.76) | -1.36 (-5.02 to 2.43) |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment
| units on a scale | NB32 | Placebo |
|---|---|---|
| Change in IWQOL-Lite Total Scores | 9.94 ± 0.41 | 6.17 ± 0.56 |
| percent change | NB32 | Placebo |
|---|---|---|
| Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data | -9.38 (-14.78 to -3.63) | -1.14 (-9.11 to 7.52) |
| percent change | NB32 | Placebo |
|---|---|---|
| Change in Fasting Insulin Levels, Using Log-transformed Data | -14.14 (-17.86 to -10.24) | -0.50 (-6.49 to 5.88) |
| mg/dL | NB32 | Placebo |
|---|---|---|
| Change in Fasting Blood Glucose Levels | -2.11 ± 0.38 | -1.73 ± 0.52 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance
| percent change | NB32 | Placebo |
|---|---|---|
| Change in HOMA-IR Levels, Using Log-transformed Data | -16.44 (-20.37 to -12.31) | -4.15 (-10.43 to 2.57) |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult
| units on a scale | NB32 | Placebo |
|---|---|---|
| Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire | -18.32 ± 0.85 | -11.09 ± 1.12 |
| mg/dL | NB32 | Placebo |
|---|---|---|
| Change in Fasting LDL Cholesterol Levels | -4.36 ± 0.90 | 0.00 ± 1.25 |
| mm Hg | NB32 | Placebo |
|---|---|---|
| Change in Systolic Blood Pressure | -0.93 ± 0.31 | -1.23 ± 0.42 |
| mm Hg | NB32 | Placebo |
|---|---|---|
| Change in Diastolic Blood Pressure | 0.20 ± 0.22 | -0.67 ± 0.30 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.
| units on a scale | NB32 | Placebo |
|---|---|---|
| Change in IDS-SR Total Score | -0.23 ± 0.17 | -0.28 ± 0.23 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).
| units on a scale | NB32 | Placebo |
|---|---|---|
| Change in Food Craving Inventory Sweets Subscale Score | -3.20 ± 0.17 | -3.18 ± 0.22 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).
| units on a scale | NB32 | Placebo |
|---|---|---|
| Change in Food Craving Inventory Carbohydrates Subscale Score | -2.68 ± 0.16 | -2.20 ± 0.21 |
Collected over Baseline, 56 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NB32/48 | — | 21/992 (2.1%) | 671/992 (67.6%) |
| Placebo | — | 7/492 (1.4%) | 244/492 (49.6%) |
| Event | NB32/48 | Placebo |
|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 1/992 | 1/492 |
| Chest painGeneral disorders | 0/992 | 1/492 |
| Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/992 | 1/492 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/992 | 1/492 |
| DizzinessNervous system disorders | 0/992 | 1/492 |
| MenorrhagiaReproductive system and breast disorders | 0/992 | 1/492 |
| Ovarian massReproductive system and breast disorders | 0/992 | 1/492 |
| Knee arthroplastySurgical and medical procedures | 0/992 | 1/492 |
| Myocardial infarctionCardiac disorders | 1/992 | 0/492 |
| PalpitationsCardiac disorders | 1/992 | 0/492 |
| Event | NB32/48 | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 290/992 | 34/492 |
| ConstipationGastrointestinal disorders | 189/992 | 35/492 |
| HeadacheNervous system disorders | 174/992 | 43/492 |
| Upper respiratory tract infectionInfections and infestations | 86/992 | 55/492 |
| InsomniaPsychiatric disorders | 97/992 | 33/492 |
| Dry mouthGastrointestinal disorders | 90/992 | 13/492 |
| VomitingGastrointestinal disorders | 84/992 | 10/492 |
| NasopharyngitisInfections and infestations | 82/992 | 40/492 |
| SinusitisInfections and infestations | 51/992 | 35/492 |
| DizzinessNervous system disorders | 68/992 | 17/492 |
All randomized subjects
| Age, Continuous(years) | NB32 | Placebo | Total |
|---|---|---|---|
| Mean | 44.27 ± 11.16 | 44.41 ± 11.38 | 44.32 ± 11.23 |
| Sex: Female, Male(Participants) | NB32 | Placebo | Total |
|---|---|---|---|
| Female | 847 | 420 | 1267 |
| Male | 154 | 75 | 229 |
| Race/Ethnicity, Customized(participants) | NB32 | Placebo | Total |
|---|---|---|---|
| White | 835 | 414 | 1249 |
| Black or African American | 133 | 72 | 205 |
| Asian | 12 | 4 | 16 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 4 |
| American Indian or Alaska Native | 10 | 2 | 12 |
| Other | 8 | 2 | 10 |
| Weight(kg) | NB32 | Placebo | Total |
|---|---|---|---|
| Mean | 100.3 ± 16.55 | 99.21 ± 15.86 | 99.95 ± 16.33 |
| BMI(kg/m^2) | NB32 | Placebo | Total |
|---|---|---|---|
| Mean | 36.22 ± 4.45 | 36.09 ± 4.27 | 36.17 ± 4.39 |
The record gives a start of Dec 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 5 years 5 months after primary completion. A results delay was requested in Oct 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naltrexone
Orexigen Therapeutics, Inc